We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-3.18%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$263M
AUM Growth
-$143M
Cap. Flow
-$77.6M
Cap. Flow %
-29.53%
Top 10 Hldgs %
50.47%
Holding
61
New
21
Increased
10
Reduced
9
Closed
20

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$22.6M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
4
MRNA icon
Moderna
MRNA
+$10.6M
5
PASG icon
Passage Bio
PASG
+$9.43M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$20.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.6M
3
APLS
Apellis Pharmaceuticals
APLS
+$18M
4
BLUE
bluebird bio
BLUE
+$17.9M
5
XLRN
Acceleron Pharma
XLRN
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$4.13M 1.57%
+446,882
New +$4.25M
TRIL
27
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.02M 1.53%
+995,600
New +$3.76M
LSACU
28
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$4M 1.52%
+400,000
New +$3.96M
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
$3.76M 1.43%
152,144
-134,880
-47% -$4.91M
IMMU
30
DELISTED
Immunomedics Inc
IMMU
$3.73M 1.42%
+276,635
New +$4.65M
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.57M 1.36%
46,399
-207,261
-82% -$18.6M
BDTX icon
32
Black Diamond Therapeutics
BDTX
$96.8M
$2.77M 1.05%
+123,465
New +$3.76M
RNAC icon
33
Cartesian Therapeutics
RNAC
$219M
$2.68M 1.02%
+37,062
New +$3.58M
MRTX
34
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.56M 0.97%
33,300
-166,700
-83% -$15M
TGTX icon
35
TG Therapeutics
TGTX
$8.33B
$2.46M 0.94%
+249,844
New +$3.16M
CYTK icon
36
Cytokinetics
CYTK
$10.7B
$2.28M 0.87%
+193,129
New +$2.46M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$2M 0.76%
69,591
-120,559
-63% -$6.98M
NERV icon
38
Minerva Neurosciences
NERV
$196M
$1.86M 0.71%
38,718
+10,239
+36% +$618K
SVRA icon
39
Savara
SVRA
$1.09B
$1.17M 0.45%
613,999
– –
RVMD icon
40
Revolution Medicines
RVMD
$38.7B
$1.16M 0.44%
+53,034
New +$1.47M
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$342M
$221K 0.08%
15,809
-207,528
-93% -$4.11M
AMRN
42
Amarin Corp
AMRN
$300M
– –
-48,128
Closed -$20.6M
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
– –
-587,108
Closed -$18M
ARDX icon
44
Ardelyx
ARDX
$1.25B
– –
-212,449
Closed -$1.59M
ASMB icon
45
Assembly Biosciences
ASMB
$501M
– –
-15,667
Closed -$3.85M
AXSM icon
46
Axsome Therapeutics
AXSM
$11.8B
– –
-124,937
Closed -$12.9M
BLUE
47
DELISTED
bluebird bio
BLUE
– –
-15,781
Closed -$17.9M
KZR
48
DELISTED
Kezar Life Sciences
KZR
– –
-12,293
Closed -$493K
MDGL icon
49
Madrigal Pharmaceuticals
MDGL
$12.5B
– –
-27,279
Closed -$2.48M
LITS
50
Lite Strategy Inc
LITS
$32.7M
– –
-57,276
Closed -$2.84M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2020 Portfolio in Review

As of Q1 2020, Logos Global Management held 61 positions worth $263M, down 35% from $406M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management withdrew a net $77.6M in Q1 2020, closing 20 positions and reducing 9 holdings. Its most notable exit was Amarin Corp, an estimated $20.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier.

Against the trend, Logos Global Management opened a new position in AbbVie worth $20.2M.

  • Logos Global Management's largest Q1 2020 buy was AbbVie: 265,600 shares worth $20.2M.
  • Logos Global Management added most to Fulcrum Therapeutics in Q1 2020, an estimated $6.54M increase.
  • Logos Global Management's biggest Q1 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $18.6M.
  • Logos Global Management fully exited Amarin Corp in Q1 2020, selling an estimated $20.6M.
  • Logos Global Management's ten largest holdings make up 50% of its $263M portfolio in Q1 2020.
  • Logos Global Management opened 21 new positions and closed 20 in Q1 2020.
  • Logos Global Management's portfolio value fell 35% quarter-over-quarter to $263M.

Based on Logos Global Management's 13F filing for Q1 2020, filed 15 May 2020.